Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Table 5

Correlation analysis of baseline characteristics and irAEs with survival outcomes.

Survival outcomes	Variable	Kaplan–Meier analysis			Cox multivariate regression analysis
		HR	95% CI		HR	95% CI
Progression-free survival	Age	0.80	0.49–1.29	0.34
	Gender	0.66	0.38–1.13	0.16
	ECOG PS	0.80	0.41–1.58	0.49
	BMI	0.59	0.36–0.96	0.030	0.67	0.40–1.13	0.1371
	Smoking	0.91	0.571.48	0.71
	Distant metastasis	0.82	0.49–1.36	0.42
	Treatment lines	1.05	0.58–1.91	0.86
	irAEs	2.02	1.25–3.26	0.0038	2.18	1.22–3.90	0.0087
Overall survival	Age	0.86	0.51–1.44	0.56
	Gender	0.78	0.41–1.46	0.46
	ECOG PS	1.04	0.51–2.09	0.92
	BMI	0.91	0.54–1.54	0.73
	Smoking	1.21	0.72–2.02	0.47
	Distant metastasis	0.69	0.40–1.19	0.16
	Treatment lines	0.97	0.53–1.79	0.86
	irAEs	1.84	1.09–3.09	0.024

^∗Indicators with statistical significance; —Represents no usability data.